Real world trial of Dificid for <em>Clostridium Difficile</em> shows less infection recurrence and cost savings - Astellas

A "real world" trial of Dificid (fidaxomicin) from Astellas/Cubist Pharma was carried out at St Georges Hospital London which showed a reduction in recurrence of Clostridium Difficile cases and savings of some �48,000 compared to treatment with vancomycin or metronidazole. Only 6% of patients treated with Dificid had a recurrence of Clostridium Difficile infection within 28 days of end of therapy compared to 20% of those taking vancomycin/metronidazole in the preceding year. Patients who already had a recurrence have a 40% risk of a further episode but there were no second recurrences reported in the Dificid treated groups.